Diabetes Mellitus Type 2

Diabetes Mellitus Type 2 – High‑Yield Study Guide for Medical Students

Definition

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia due to a combination of peripheral insulin resistance, progressive β‑cell dysfunction, and inappropriate hepatic glucose production. It is heterogeneous, with distinct phenotypes and comorbidity patterns now recognized using clustering approaches.[5]

Epidemiology

T2DM accounts for 90–95% of all diabetes cases worldwide and is a major contributor to cardiovascular disease, chronic kidney disease, blindness, and non‑traumatic amputations.[5] Prevalence is rising globally, driven by aging populations, urbanization, sedentary lifestyles, and obesity.

Risk is higher in individuals with central obesity, a family history of T2DM, prior gestational diabetes, polycystic ovary syndrome, and in many ethnic minority groups. Emerging data highlight substantial heterogeneity in comorbidities and complications across subgroups of T2DM, emphasizing the need for individualized risk stratification.[5]

Pathophysiology

T2DM results from an interplay of insulin resistance and β‑cell dysfunction on a background of genetic susceptibility and environmental factors.

• Insulin resistance: Skeletal muscle, adipose tissue, and liver become less responsive to insulin. In muscle, glucose uptake via GLUT4 is reduced; in adipose tissue, lipolysis increases, raising free fatty acids; in the liver, insulin fails to suppress gluconeogenesis, leading to fasting hyperglycemia.
• β‑cell dysfunction: To compensate for insulin resistance, pancreatic β‑cells initially increase insulin secretion. Over time, glucotoxicity, lipotoxicity, inflammation, and genetic factors drive β‑cell exhaustion, loss of first‑phase insulin response, and eventual relative insulin deficiency.
• Incretin effect and α‑cell dysregulation: Impaired GLP‑1 and GIP responses reduce postprandial insulin secretion, while inappropriate glucagon secretion exacerbates hepatic glucose output.
• Adipose tissue dysfunction: Visceral adiposity produces pro‑inflammatory cytokines (e.g., TNF‑α, IL‑6) and adipokine imbalance (↓adiponectin), promoting systemic insulin resistance.
• Heterogeneous subtypes: Clustering algorithms have identified T2DM subgroups (e.g., mild obesity‑related, severe insulin‑resistant, mild age‑related) with differing complication risks (e.g., nephropathy vs. retinopathy predominance), which may eventually guide personalized therapy.[5]

Clinical Presentation

T2DM has a long asymptomatic phase and is frequently detected incidentally on screening or during evaluation for complications.

• Classic symptoms of hyperglycemia (often mild or absent at onset):
  • Polyuria
  • Polydipsia
  • Polyphagia
  • Unintentional weight loss (less pronounced than in type 1 DM)
  • Fatigue and blurred vision
• Associated features:
  • Overweight or obesity, central adiposity
  • Acanthosis nigricans (marker of insulin resistance)
  • Hypertension, dyslipidemia (high triglycerides, low HDL)
  • Recurrent infections (e.g., candidal vulvovaginitis, skin infections, urinary tract infections)[3]
• Presentation with complications:
  • Cardiovascular disease: angina, MI, stroke, claudication
  • Neuropathy: distal symmetric sensory loss, neuropathic pain, foot ulcers, autonomic symptoms (e.g., orthostatic hypotension, gastroparesis)
  • Nephropathy: albuminuria, progressive CKD
  • Retinopathy: visual impairment
  • Infections: including opportunistic pulmonary infections in poorly controlled diabetes, such as invasive candidiasis and tuberculosis.[3]

Diagnosis

The diagnosis of T2DM is based on blood glucose or HbA1c criteria, confirmed on a separate day unless unequivocal hyperglycemia with symptoms is present.

• Diagnostic criteria for diabetes (use any one of the following, confirmed on repeat testing):
  • Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) after at least 8 hours fast
  • 2‑hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during a 75 g oral glucose tolerance test (OGTT)
  • HbA1c ≥ 6.5% (48 mmol/mol), using a standardized assay
  • Random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis
• Prediabetes (high‑risk state):
  • FPG 100–125 mg/dL (5.6–6.9 mmol/L)
  • 2‑hour OGTT 140–199 mg/dL (7.8–11.0 mmol/L)
  • HbA1c 5.7–6.4%
• Initial evaluation at diagnosis should include assessment for comorbidities and complications, aligned with the known heterogeneity of T2DM phenotypes:[5]
  • Blood pressure, BMI, waist circumference
  • Lipid profile
  • Serum creatinine, eGFR; urine albumin-to-creatinine ratio
  • Comprehensive eye exam for retinopathy
  • Foot exam for neuropathy and ulcers
  • Screening for cardiovascular disease depending on age and risk factors

Management

Management integrates lifestyle modification, structured nutrition, glucose‑lowering pharmacotherapy, and comprehensive cardiovascular risk reduction. Emerging data suggest individualized strategies based on T2DM subtypes and complication risk clusters.[5]

Glycemic Targets

• For many non‑pregnant adults, aim for HbA1c < 7% if achievable without significant hypoglycemia.
• Less stringent goals (e.g., < 8%) may be appropriate in older patients, those with comorbidities, limited life expectancy, or high hypoglycemia risk.
• More stringent goals (≤ 6.5%) may be reasonable in younger patients with short disease duration and low risk of hypoglycemia.

Lifestyle and Nutrition Therapy

Medical nutrition therapy and lifestyle modification are foundational and should be initiated at diagnosis and reinforced regularly.

• Dietary strategies:
  • Caloric restriction for weight loss in overweight/obese patients (typically 500–750 kcal/day deficit).
  • Emphasis on vegetables, whole grains, legumes, lean proteins, and unsaturated fats; limit refined carbohydrates, sugar‑sweetened beverages, and processed foods.
  • Low‑carbohydrate, Mediterranean, or other structured eating patterns may improve glycemic control; choice should be individualized.
  • Continuous glucose monitoring (CGM) can be used to tailor food choices and timing to improve Time in Range, even in non‑insulin‑treated T2DM, as shown in trials such as UNITE.[2]
• Physical activity:
  • At least 150 minutes/week of moderate‑intensity aerobic activity, spread over ≥ 3 days/week, with no more than 2 consecutive days without exercise.
  • Resistance training at least 2–3 days/week to improve insulin sensitivity and preserve muscle mass.
• Weight management:
  • Target ≥ 5–10% weight loss in overweight/obese patients; larger weight loss improves glycemia and may induce remission in early T2DM.
  • Consider pharmacologic anti‑obesity agents or metabolic/bariatric surgery in patients with severe obesity and inadequate response to lifestyle measures.

Pharmacologic Therapy

Choice of therapy should consider efficacy, impact on weight, hypoglycemia risk, comorbidities (ASCVD, HF, CKD), cost, and patient preference. The heterogeneity of T2DM means that certain subgroups benefit more from specific drug classes.[5]

First‑Line Therapy

• Metformin
  • Typically first‑line agent unless contraindicated (e.g., significant renal impairment, intolerance).
  • Mechanism: decreases hepatic gluconeogenesis, improves peripheral insulin sensitivity.
  • Benefits: weight neutral or modest weight loss, low hypoglycemia risk, favorable cost profile.

Second‑Line and Add‑On Therapy

Additional agents are chosen based on clinical phenotype and comorbidities.

• SGLT2 inhibitors (e.g., empagliflozin, canagliflozin, dapagliflozin)
  • Promote urinary glucose excretion; reduce weight and blood pressure.
  • Evidence supports cardiovascular and renal protection in appropriate patients (ASCVD, HF, CKD).
• GLP‑1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide)
  • Enhance glucose‑dependent insulin secretion, suppress glucagon, slow gastric emptying, reduce appetite.
  • Produce significant weight loss; some agents have demonstrated cardiovascular benefit.
• DPP‑4 inhibitors (e.g., sitagliptin, linagliptin)
  • Increase endogenous incretin levels; weight neutral, low hypoglycemia risk.
  • Moderate glycemic efficacy; often used when GLP‑1 RAs are not suitable.
• Thiazolidinediones (TZDs) (e.g., pioglitazone)
  • Improve insulin sensitivity in muscle and adipose tissue.
  • Side effects: weight gain, edema, HF exacerbation, fracture risk; use selectively.
• Sulfonylureas and meglitinides
  • Increase insulin secretion independent of glucose; effective but increase hypoglycemia risk and weight gain.
  • Often used where cost is a major issue, with careful monitoring.
• Basal insulin
  • Indicated when oral/non‑insulin injectable agents fail to achieve glycemic targets or if there is severe hyperglycemia, catabolic symptoms, or marked HbA1c elevation.
  • Start with low dose and titrate based on fasting glucose; continue metformin and other agents as appropriate.

Cardiovascular and Renal Risk Reduction

• Blood pressure control: Usually target < 130/80 mmHg depending on overall risk; ACE inhibitors or ARBs preferred in patients with albuminuria.
• Lipid management: Statin therapy in most adults with T2DM; intensity based on age and ASCVD risk.
• Antiplatelet therapy: Low‑dose aspirin for secondary prevention, and selectively for high‑risk primary prevention.
• Kidney protection: ACEi/ARB and SGLT2 inhibitors in appropriate patients slow CKD progression; monitor albuminuria and eGFR regularly.[5]

Comprehensive Care and Complication Screening

• Annual eye exams for diabetic retinopathy.
• Regular foot exams for neuropathy, deformities, calluses, and ulcers.
• Neuropathy assessment using monofilament and vibration testing.
• Vaccinations: Influenza, pneumococcal, hepatitis B, and others per guidelines.
• Infection vigilance: Poorly controlled T2DM increases susceptibility to opportunistic infections such as pulmonary candidiasis and tuberculosis; multidisciplinary management may be required.[3]

Nutrition, Sarcopenia, and Chronic Disease

With aging and chronic comorbidities (e.g., heart failure, CKD), T2DM patients are at risk for malnutrition and sarcopenia, which worsen outcomes and glycemic variability.[1] Integrating nutritional screening and resistance exercise can help maintain muscle mass and functional status, especially in older adults.

• Consider formal nutritional assessment in elderly patients with T2DM and comorbid CHF, CKD, or frailty.
• Address protein intake and resistance training to reduce the risk of sarcopenia and disability.[1]

Psychosocial Aspects and Stigma

Language and communication around diabetes significantly affect patient engagement, self‑management, and perceptions of stigma.[4] Medical students should be aware of the impact of judgmental or blame‑oriented language on people living with T2DM.

• Use person‑first language (e.g., “person living with diabetes” rather than “diabetic”).
• Avoid framing T2DM as solely the result of personal failure; acknowledge biological, social, and environmental contributors.[4]
• Collaborative goal‑setting and empathetic communication improve adherence and outcomes.

Key Clinical Pearls for Exams and Practice

• T2DM is heterogeneous: Phenotypic clusters differ in complication risk (e.g., nephropathy‑predominant vs. retinopathy‑predominant), which will increasingly influence individualized therapy.[5]
• Always think beyond glucose: Management goals include cardiovascular, renal, and hepatic protection, not just HbA1c reduction.
• Consider SGLT2 inhibitors or GLP‑1 RAs early in patients with ASCVD, HF, or CKD for organ protection, independent of baseline HbA1c.
• Unexplained weight loss, fatigue, and infections in an overweight or older adult warrant screening for T2DM.
• Recurrent candidal or atypical infections, particularly pulmonary or systemic fungal infections, may be a clue to undiagnosed or poorly controlled diabetes.[3]
• In older patients with CHF and T2DM, screen for malnutrition and sarcopenia, which are common and prognostically important.[1]
• Use CGM data to teach nutrition: Even in non‑insulin‑treated T2DM, CGM can guide real‑time dietary adjustments to improve Time in Range.[2]
• Language matters: Non‑stigmatizing communication improves engagement and self‑care in people with T2DM and reduces the experience of diabetes‑related stigma.[4]

Summary

Type 2 Diabetes Mellitus is a common, heterogeneous metabolic disease driven by insulin resistance and β‑cell dysfunction, with wide‑ranging microvascular and macrovascular complications. Accurate diagnosis, early lifestyle intervention, individualized pharmacotherapy (including cardiorenal protective agents), and attention to nutritional status, infection risk, and psychosocial factors are essential. Emerging clustering approaches are refining our understanding of T2DM subtypes and will likely shape future precision‑medicine strategies in diabetes care.[5]